Redeye states that Enea showed solid sales growth while EBITDA margin were slightly below expectations. It sees uncertainty with the CEO transition and EBITDA headwinds from the Operating System, while an investor-friendly capital return policy and M&A opportunities are possibilities. Redeye makes minor revisions to its estimates and fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/